{"id":"NCT02605954","sponsor":"Gilead Sciences","briefTitle":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","officialTitle":"A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Abacavir/Lamivudine (ABC/3TC) Plus a Third Antiretroviral Agent to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adult Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11-18","primaryCompletion":"2017-06-14","completion":"2018-01-24","firstPosted":"2015-11-17","resultsPosted":"2018-07-13","lastUpdate":"2018-11-14"},"enrollment":275,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["HIV-1 Infection"],"interventions":[{"type":"DRUG","name":"E/C/F/TAF","otherNames":["GenvoyaÂ®"]},{"type":"DRUG","name":"ABC/3TC","otherNames":["Epzicom","Kivexa"]},{"type":"DRUG","name":"Third Antiretroviral Agent","otherNames":[]}],"arms":[{"label":"E/C/F/TAF","type":"EXPERIMENTAL"},{"label":"ABC/3TC+3rd Agent","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to evaluate the efficacy of switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) relative to continuing on a baseline regimen consisting of abacavir/lamivudine (ABC/3TC) plus a 3rd antiretroviral agent in HIV-1 infected participants.","primaryOutcome":{"measure":"Percentage of Participants Who Have HIV-1 RNA < 50 Copies/mL as Defined by the FDA Snapshot Algorithm at Week 24","timeFrame":"Week 24","effectByArm":[{"arm":"E/C/F/TAF","deltaMin":93.4,"sd":null},{"arm":"ABC/3TC+3rd Agent","deltaMin":97.8,"sd":null},{"arm":"Delayed E/C/F/TAF","deltaMin":96.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.15"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":null},"locations":{"siteCount":49,"countries":["United States","France","Germany","Italy","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":183},"commonTop":["Diarrhoea","Headache","Arthralgia","Vitamin D deficiency","Upper respiratory tract infection"]}}